The drug is approved to address specific symptoms associated with irritable bowel syndrome with diarrhea (IBS-D) in adults.

Quick Facts: Main Therapeutic Domains
Condition Addressed: Irritable bowel syndrome with diarrhea (IBS-D)
Primary Use: To help manage the symptoms of IBS-D
Benefits May Include: Potential relief from abdominal pain and improved stool consistency

Truberzi is indicated for the treatment of adults diagnosed with irritable bowel syndrome with diarrhea (IBS-D). Its therapeutic domain focuses on managing the primary manifestations of this condition.

Use of this medication may assist in reducing the frequency of diarrhea and may help provide relief from abdominal discomfort or pain associated with IBS-D. It is an option for adults whose symptoms have not responded adequately to other standard treatments. The goal of the therapy is to help patients manage their condition and improve aspects of their daily function.

Truberzi (eluxadoline) is for use only in adults (18 years and older). It is not recommended for children and adolescents, as its safety and effectiveness have not been established in these populations.

Regulatory agencies have specified that Truberzi is contraindicated (must not be used) in several specific patient groups due to the increased risk of serious adverse reactions, particularly pancreatitis and sphincter of Oddi spasm. These include patients who:

• Do not have a gallbladder (e.g., due to cholecystectomy).
• Have a history of pancreatitis or structural diseases of the pancreas, including pancreatic duct obstruction.
• Have known or suspected biliary duct obstruction or sphincter of Oddi disease or dysfunction.
• Have severe hepatic impairment (Child-Pugh Class C).
• Have a history of chronic or severe constipation or known or suspected mechanical gastrointestinal obstruction.
• Are engaging in alcoholism, alcohol abuse, or chronic/acute excessive alcohol use.
• Have a known hypersensitivity reaction to the medicine or its ingredients.
• Are taking potent OATP1B1 inhibitor medications (e.g., cyclosporine).

Use in patients with mild or moderate hepatic impairment is not contraindicated but requires a dose reduction and monitoring. This careful eligibility profile is strictly defined in governmental regulatory documents to mitigate the risks associated with the drug's mechanism of action.

Interactions with other medicines and products

The interaction profile of Truberzi (Eluxadoline) is defined by pharmacokinetic and pharmacodynamic constraints, as documented in official regulatory labeling. Co-administration with strong inhibitors of the OATP1B1 transporter (such as Cyclosporine or Gemfibrozil) is formally contraindicated because this interaction significantly increases the concentration of Eluxadoline in the body. Similarly, Eluxadoline acts as an inhibitor of the OATP1B1 transporter, which may result in increased systemic exposure of co-administered OATP1B1 substrates, including Rosuvastatin.

Restrictions and Contraindicated Combinations

Interaction Type	Substance or Condition	Regulatory Status
Pharmacokinetic	Strong OATP1B1 Inhibitors	Contraindicated
Substance Interaction	Alcohol (Heavy Use)	Contraindicated
Pharmacodynamic	Other Constipation-Causing Medicines	Avoided

Use is also contraindicated in patients with a history of alcohol abuse or those who regularly consume more than three alcoholic beverages per day, due to an officially documented risk of acute pancreatitis. A restriction is placed on combining Eluxadoline with other medicines that cause constipation, such as Opioids or Loperamide, to avoid additive pharmacodynamic effects that increase the risk of severe constipation or bowel obstruction.

Population-specific exposure concerns lead to a restriction in severe hepatic impairment, where Eluxadoline use is contraindicated due to a large increase in its systemic levels. The official labeling does not specify mandatory timing separation rules (e.g., 'administer X hours apart') for any interacting substance.

The mechanism of action of Eluxadoline (Truberzi) is defined by its highly localized, targeted modulation of opioid receptors within the bowel wall, resulting in a mixed inhibitory and modulatory physiological response.

---

Targeting Opioid Receptors for Balanced Regulation

Eluxadoline acts as a partial agonist at the mu-opioid receptor (muOR) and an antagonist at the delta-opioid receptor (deltaOR), primarily engaging targets within the Enteric Nervous System (ENS). This dual agonism-antagonism profile is crucial, as the deltaOR antagonism serves to counteract the extreme motility suppression typically associated with unopposed muOR agonism, resulting in a modulated inhibitory effect on motility.

---

Modulating Motility and Fluid Secretion Pathways

The activation of muORs leads to a reduction in excitatory neurotransmitter release from ENS neurons, which, in turn, decreases the frequency of smooth muscle contractions and inhibits the secretion of water and electrolytes into the intestinal lumen. This combination of effects initiates a molecular cascade that results in a slower overall transit time and less fluid content in the stool, resulting in a state of reduced GI tract hypermotility and hypersecretion.

Official Administration Guidelines for Truberzi

The use of Truberzi (Eluxadoline) is governed by specific instructions concerning the route, dose, and frequency.

---

Administration Scope

Property	Official Instruction
Route of Administration	The medicine is taken orally as a film-coated tablet.
Dosing Schedule	The standard recommended dose is 100 mg twice daily.
Timing in Relation to Meals	Must be taken with food (e.g., morning and evening).
Preparation Requirements	None specified; the tablets are intended to be swallowed whole.
Age-Group Administration	Safety and effectiveness have not been established for use in pediatric patients (0–17 years).
Missed-Dose Rules	If a dose is missed, take the next dose at the regular time; do not take two doses at once to make up for the missed dose.
Special Procedural Conditions	The medicine must be discontinued if severe constipation develops and persists for more than four days.

---

Population-Specific Dosing

The dose is reduced to 75 mg twice daily for specific patient populations. This lower dose is used for patients with mild or moderate hepatic impairment and those receiving concomitant medication that acts as an OATP1B1 inhibitor. For patients who are unable to tolerate the 100 mg dose, the 75 mg dose is also specified as the appropriate alternative.

---

Resulting Procedural Structure

The official protocol dictates a consistent regimen of oral intake, always paired with a meal, and defines clear criteria for dose adjustments and cessation. The fixed frequency and administration conditions ensure consistent use.

Research Evidence / Overview of Studies

Phase III Clinical Trial Findings

Research has explored a compound characterized by its ability to modulate the COX-2 pathway. The study design included evaluation of time-dependent outcomes.

• Studies have evaluated whether the compound affects joint function and examined its impact on reported pain levels in patients with osteoarthritis.
• Research data indicates that studies evaluated changes in morning stiffness, with observations recorded after the first week of assessment.
• A separate line of research compared the compound's profile against non-selective NSAIDs, specifically examining gastrointestinal events.

---

Large-Scale Evaluation (RCT)

Further research involved a randomized controlled trial (RCT) with 400 subjects to evaluate the compound.

• This trial included subjects diagnosed with knee and hip osteoarthritis, comparing the compound to a placebo and an active comparator.
• Pharmacokinetic assessments within the study protocol included evaluations of the compound's absorption profile.

---

Combination Therapy Research

Studies have explored the effects of administering the compound in combination with an existing slow-acting drug.

• One trial included a comparison to treatment X in a subgroup of patients over 65.
• Studies tracked the reported need for rescue medication, with data recorded after three days.
• Research has examined the compound's profile in subjects based on pre-defined criteria, which included certain aspects of renal function. The exclusion criteria for the trials specified that subjects with severe kidney issues were not included.

Common questions about Truberzi (FAQ)

---

Q: Is Truberzi a narcotic or a controlled substance?

A: Yes, Truberzi is regulated as a controlled substance in the United States. The active ingredient, Eluxadoline, is classified by the U.S. Drug Enforcement Administration (DEA) as a Schedule IV substance. This classification indicates that the drug has an accepted medical use and a low potential for abuse relative to other scheduled substances.

---

Q: What are common user experiences with Truberzi?

A: Official clinical trial data primarily details the likelihood of adverse reactions such as constipation, nausea, and abdominal pain. In terms of mental state, the official information also notes that effects like 'euphoric mood' and 'feeling drunk' were reported in a very small percentage (le2%) of patients in clinical trials. These experiences reflect the drug's activity on the opioid receptors in the gut.

---

Q: Are there any long-term effects of taking Truberzi that are officially noted?

A: Regulatory documents state that clinical trials were designed to support continuous use of the medication. Studies evaluating the safety and effectiveness of the drug have included patient exposure for up to one year. Official data from these studies included patient exposure for up to one year, which represents the maximum duration of continuous use studied in controlled trials.

---

Q: Do any foods or drinks need to be avoided while using Truberzi?

A: The official product information specifically lists a major restriction regarding alcohol. The medicine is formally prohibited (contraindicated) for patients who have a history of alcohol abuse or those who regularly consume more than three alcoholic beverages per day, due to a known risk of pancreatitis.

---

Q: Does Truberzi cause changes in weight or appetite?

A: Official adverse reaction data includes loss of appetite (anorexia) as a reported but rare side effect. Significant changes in body weight are generally not listed as common or frequent reactions in the regulatory documentation.

---

Q: Is Truberzi known to affect sleep patterns?

A: Official documentation reports that some patients in clinical trials experienced central nervous system (CNS) effects. These effects included somnolence (drowsiness) and sedation in a small percentage (le2%) of patients.

---

Q: Is Truberzi considered safe for older adults or seniors?

A: Regulatory documents include specific notes for older patients (aged 65 years and over). Official notes indicate that older adults (ge65 years) have shown a higher proportion of adverse reactions and may be more sensitive to the effects of the medicine.

---

Q: Does Truberzi require regular blood work or monitoring?

A: The official labeling states that blood tests may be needed to check progress and monitor for potential unwanted effects, particularly concerning the liver and pancreas, at regular visits.

---

Q: How long does it usually take to notice the effects of Truberzi?

A: Initial assessment phases of clinical trials focused on changes observed as early as one week after starting treatment, with efficacy being measured over 26 weeks. This indicates that assessments of effect occurred relatively early in the treatment period.

---

Q: Is Truberzi a long-term treatment?

A: Studies conducted during the drug's development and regulatory review were specifically designed to evaluate the compound for continuous long-term use. This classification aligns with its intended purpose for a chronic condition.

---

Q: Are there any restrictions on driving or operating machinery while taking Truberzi?

A: The official labeling contains warnings related to impaired mental or physical abilities. The label includes warnings that certain patients, particularly those with hepatic impairment, should be monitored for impaired mental or physical abilities, and that activities requiring mental alertness, such as driving, should be approached with caution.

---

Q: Can Truberzi be used during pregnancy, according to official documents?

A: Regulatory risk summaries state there are no available data on the use of this drug in pregnant women to inform a drug-related risk. While animal studies did not indicate direct harm to the developing fetus, there are no controlled human data.

---

Q: What are the official recommendations for using Truberzi while breastfeeding?

A: Official safety summaries indicate that there is no data on the presence of the drug in human milk, the effects on the breastfed infant, or the effect on milk production.

---

Q: What percentage of people in clinical trials experienced the main effect of Truberzi?

A: Clinical trials defined a composite response as the simultaneous improvement of the two main symptoms (pain and stool consistency). In one 26-week study, approximately 29% of patients taking the drug at the recommended dose achieved this composite improvement, compared with 19% of patients taking a placebo.

---

Q: Does Truberzi cause allergic reactions?

A: Official safety information lists hypersensitivity reactions, including anaphylaxis, as a serious adverse reaction that has been reported. The label states that if signs of a hypersensitivity reaction develop, use of the medicine should be discontinued immediately, as hypersensitivity is a serious reported adverse reaction.

---

Q: Can Truberzi affect mental health or mood?

A: Official safety data confirms that effects on mood are possible due to the drug’s mechanism of action. Euphoric mood was reported in a very small percentage (le2%) of patients in clinical trials.

---

Q: What is the maximum time Truberzi is studied for continuous use?

A: Regulatory reviews indicate that patients participating in controlled clinical trials were exposed to the medicine for up to one year. This represents the maximum duration of continuous use for which official safety data was gathered.

---

Q: Are there official reports about long-term dependency on Truberzi?

A: Regulatory reviews and its classification as a Schedule IV controlled substance indicate that the drug has a low potential for abuse and minimal expected risk of long-term dependence or addiction based on its properties.

The storage and disposal of Truberzi (eluxadoline) tablets must follow the exact requirements stated in the official regulatory labeling.

Official Storage Requirements

Condition	Regulatory Specification
Temperature	Store at Controlled Room Temperature, 20 C to 25 C (68 F to 77 F). Temporary excursions are permitted from 15 C to 30 C (59 F to 86 F).
Protection	Keep the product from freezing, excessive heat, moisture, and light.
Container	Store in the original container and ensure it is tightly closed.

Child-Safety and Disposal

It is an explicit requirement to keep Truberzi out of the reach of children, storing the medicine in a secure location out of sight. Outdated or no longer needed medicine must be discarded. Official guidelines require consultation with a healthcare professional or local waste disposal service for the proper method of disposing of unused medicine, and general caution advises against flushing products down a toilet or drain.